NCT02390544View on ClinicalTrials.gov

A Pharmacokinetic Study of Melphalan in Children

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 8, 2015

Primary Completion Date

September 22, 2018

Study Completion Date

September 23, 2018

Conditions
Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Melphalan

Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02390544 - A Pharmacokinetic Study of Melphalan in Children | Biotech Hunter | Biotech Hunter